Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 29, 2025
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
GlobeNewswire
·
April 29, 2025
WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has …
Oxford-Harrington Rare Disease Centre Appoints Majid Jafar to its Advisory Council
GlobeNewswire
·
April 29, 2025
Mr. Jafar is a distinguished international business leader and co-founder of the Loulou Foundation OXFORD, UK and CLEVELAND, Ohio, US, 29 April 2025 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and …
EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting
GlobeNewswire
·
April 29, 2025
Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120th AUA Annual Meeting on Sunday, April 27, 2025. Study achieved its primary endpoint and demonstrated that the rate of treatment …
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
GlobeNewswire
·
April 29, 2025
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race Paris, April 29, 2025. Sanofi is proud to unveil an exciting new chapter in its mission to fight meningitis, as it …
Communiqué de presse :
GlobeNewswire
·
April 29, 2025
Quand chaque seconde compte : Sanofi, McLaren Racing et United Autosports s'unissent pour sensibiliser à la méningite aux 24 Heures du Mans Paris, le 29 avril 2025. Sanofi est fière de présenter une nouvelle étape significative dans sa mission de lutte …
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
GlobeNewswire
·
April 29, 2025
PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial …
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
GlobeNewswire
·
April 29, 2025
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune …
RTOERO honours a lifetime champion for seniors: Susan Walsh receives the Award for Eminent Contribution
GlobeNewswire
·
April 29, 2025
Toronto, Ontario, April 29, 2025 (GLOBE NEWSWIRE) -- Susan Walsh of Newfoundland has been named the second ever recipient of the RTOERO Award for Eminent Contribution to Seniors in Canada. Her career has taken her from the frontlines to policymaking in …
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
GlobeNewswire
·
April 29, 2025
MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including …
Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2025
GlobeNewswire
·
April 29, 2025
BANNOCKBURN, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results …
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
GlobeNewswire
·
April 29, 2025
CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren’s disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no …
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences
GlobeNewswire
·
April 29, 2025
BEDFORD, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific …
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
GlobeNewswire
·
April 29, 2025
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference …
Skye Bioscience to Participate in May Investment and Medical Conferences
GlobeNewswire
·
April 29, 2025
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will …
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
GlobeNewswire
·
April 29, 2025
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first …
EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy
GlobeNewswire
·
April 29, 2025
Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial for patients with relapse or refractory multiple …
Ostarine Mk-2866 SARMs: Ostarine Cycle, Osta 2866 Benefits, Ostarine PCT, Ostarine Mk-2866 Dosage, Osta 2866 Side Effects, What Is Ostarine, Buy, Before and After By CrazyBulk
GlobeNewswire
·
April 29, 2025
New York , April 29, 2025 (GLOBE NEWSWIRE) -- NEW YORK, April 28, 2025: Crazy Bulk OSTA 2866: A Safe Alternative to Ostarine MK 2866 Crazy Bulk OSTA 2866 is a safe and legal substitute for Ostarine MK 2866. We now have a new type of bodybuilding …
Regeneron Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
April 29, 2025
First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22 First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 billion versus first quarter 2024 First quarter 2025 EYLEA …
Semen & Cum Pills - Best Volume Pills of 2025 (Supplements for Bigger Loads) - By Semanax
GlobeNewswire
·
April 29, 2025
Limassol, Cyprus, April 29, 2025 (GLOBE NEWSWIRE) -- Particularly in the male enhancement pills industry, Semenax Volume Pills are arguably the best rated and most trusted cum pills for men wanting to increase the volume of their semen, heighten their …
Prime Biome Safety Report 2025: Exposing Review Scams, Customer Complaints & Safe Buying Options
GlobeNewswire
·
April 29, 2025
St. Petersburg, Florida, April 29, 2025 (GLOBE NEWSWIRE) -- PrimeBiome is kind of blowing up right now (Rating: 4.97/5), and for good reason. People are raving about smoother digestion, way less bloating, and that glow-up skin vibe. It's a smart, science- …